Ariosa's proprietary Harmony Prenatal Test has been validated to CLIA requirements
Roche has announced the acquisition of Ariosa Diagnostics, a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology.
Ariosa's proprietary Harmony Prenatal Test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories.
"The acquisition of Ariosa is another example of Roche's commitment to advanced molecular diagnostics. Circulating cfDNA has the promise of providing early diagnostic information through a simple blood test in many important segments including pregnancy, cancer and transplantation, aligning with our strategy in personalised healthcare and commitment to setting new standards of care," said Mr Roland Diggelmann, COO, Roche Diagnostics Division.
"We are thrilled to join forces with Roche to continue in our commitment to bringing forward high quality and affordable genetic testing that positively impacts the medical care of patients around the world," said Mr Ken Song MD, chief executive officer, Ariosa.
The closing of the transaction is expected to take place in December, 2014.
